Date: 2013-10-07
Type of information: R&D agreement
Compound: ISIS-GSK3Rx
Company: Isis Pharmaceuticals (USA - CA) GSK (UK)
Therapeutic area:
Type agreement: R&D
licensing
Action mechanism: ISIS-GSK3Rx is an antisense drug designed to inhibit the production of an undisclosed target to treat a common viral infection.
Disease: undisclosed infectious disease
Details: * On October 7, 2013, Isis Pharmaceuticals has announced that GSK has added a development candidate ISIS-GSK3Rx, to its collaboration with Isis. Isis earned $7 million in milestone payments associated with the advancement of this program. ISIS-GSK3Rx is an antisense drug designed to inhibit the production of an undisclosed target to treat a common viral infection. Isis will develop ISIS-GSK3Rx to Phase 2 proof-of-concept, after which GSK has an exclusive option to in-license the program and further develop and commercialize the asset. As a part of the alliance, Isis is eligible to earn additional pre-licensing milestone payments from GSK as ISIS-GSK3Rx advances. Isis is also eligible to receive double-digit royalties on sales of ISIS-GSK3Rx. The alliance applies Isis\' antisense drug discovery platform to discover and develop new therapeutics against targets for rare and/or serious diseases.
Financial terms: In March 2010, GSK and Isis Pharmaceuticals have announced a strategic alliance that will apply the Isis antisense drug discovery platform to seek out and develop new therapeutics against targets for rare and serious disease, including infectious diseases and some conditions causing blindness. Under the terms of the agreement, which covers up to six programs, Isis will receive an upfront $35 million payment from GSK and is eligible to receive on average up to $20 million in milestones per program up to Phase 2 proof-of-concept (PoC). GSK will have the option to license compounds at PoC, and will be responsible for all further development and commercialization. Isis will be eligible to receive license fees and milestone payments, totaling nearly $1.5 billion, in the event all six programs are successfully developed for one or more indications and commercialized through to pre-agreed sales targets. In addition, Isis will receive up to double-digit royalties on sales from any product that is successfully commercialized.
Latest news:
